This article contains promotional content. (September 2023) |
Company type | Public |
---|---|
Industry | Pharmaceuticals |
Founded | April 7, 2014 |
Founder | Vivek Ramaswamy |
Headquarters | 151 West 42nd Street New York, NY 10036 U.S. |
Key people | Matt Gline (CEO) |
Revenue | US$125 million (2024) |
US$4.24 billion (2024)[a] | |
US$4.35 billion (2024)[a] | |
Total assets | US$7.22 billion (2024)[a] |
Total equity | US$6.45 billion (2024)[a] |
Owner | Vivek Ramaswamy (10.5%) |
Number of employees | 908 (2024) |
Website | roivant |
Footnotes / references Financials as of 31 March 2024[update].[1][2] |
Roivant Sciences Ltd. is an American multinational healthcare company focused on applying technology to drug development and building subsidiary life sciences and health technology companies. It was founded in 2014 by Vivek Ramaswamy and is currently headed by CEO Matt Gline.[3] Roivant maintains its headquarters in New York City as well as major offices in the biotech hubs of Boston and Basel.
Cite error: There are <ref group=lower-alpha>
tags or {{efn}}
templates on this page, but the references will not show without a {{reflist|group=lower-alpha}}
template or {{notelist}}
template (see the help page).